// App-Quantinova.ai

POS0679 (2022) : CLINICAL OUTCOMES UP TO WEEK (W) 48 IN THE ONGOING FILGOTINIB (FIL) LONG-TERM EXTENSION (LTE) TRIAL OF RHEUMATOID ARTHRITIS (RA) PATIENTS (pts) WITH INADEQUATE RESPONSE (IR) TO METHOTREXATE (MTX) INITIALLY TREATED WITH FIL OR ADALIMUMAB (ADA) DURING THE PHASE 3 PARENT STUDY (PS)

Researchers

Presenter

  • B. Combe

Principal Investigators

  • Y. Tanaka

  • P. Emery

  • A. Pechonkina

  • A. Kuo

  • Q. Gong

  • K. Van Beneden

  • V. Rajendran

  • H. Schulze-Koops

Medical Centers

  • Hospital Center University De Montpellier, Rhumatologie, Montpellier, France

  • University of Occupational and Environmental Health, The First Department of Internal Medicine, Fukuoka, Japan

  • University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, United Kingdom

  • Gilead Sciences, Inc., Clinical Development, Foster City, United States of America

  • Gilead Sciences, Inc., Biostatistics, Foster City, United States of America

  • Galapagos NV, Medical Affairs, Mechelen, Belgium

  • Galapagos NV, Development, Mechelen, Belgium

  • Ludwig-Maximilians-University, Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Munich, Germany

Locations

  • France

  • Japan

  • United Kingdom

  • United States

  • Belgium

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Methotrexate

  • Adalimumab

  • Filgotinib

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT02889796

  • NCT03025308

Sponsors

  • Gilead Sciences

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved